Clinical trial
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic…
NCT00324870 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00324870 |
|---|---|
| Title | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer |
| Official title | Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | vorinostat, bevacizumab |
| Enrollment | 37 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | May 11, 2006 |
| Last update posted | Jan 13, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: